Use of the ShangRing circumcision device in boys below 18 years old in Kenya: results from a pilot study

Quentin D Awori, Richard K Lee, Phillip S Li, Jared N Moguche, Dan Ouma, Betsy Sambai, Marc Goldstein, Mark A Barone, Quentin D Awori, Richard K Lee, Phillip S Li, Jared N Moguche, Dan Ouma, Betsy Sambai, Marc Goldstein, Mark A Barone

Abstract

Introduction: Male circumcision is a proven prevention strategy against the spread of HIV. The World Health Organization's new 2016-2021 strategic framework on voluntary medical male circumcision (VMMC) targets 90% of males aged 10-29 years to receive circumcision by 2021 in 14 priority sub-Saharan countries while anticipating an increase in the demand for infant circumcision. It also states that the use of circumcision devices is a safe and efficient innovation to accelerate attainment of these goals. The primary objective of this pilot study was to evaluate the safety and acceptability of the ShangRing, a novel circumcision device, in boys below 18 years of age.

Methods: A total of 80 boys, 3 months to 17 years old, were circumcised using the no-flip ShangRing technique. All rings were removed 5-7 days later. Participants were evaluated weekly until the wound was completely healed. Data on procedure times, adverse events (AEs), time to clinical wound healing and satisfaction were recorded and analysed.

Results: Nearly all (79/80, 98.8%) circumcisions were successfully completed using the no-flip ShangRing technique without complications. In one (1.2%) case, the outer ring slipped off after the foreskin was removed and the procedure was completed by stitching. The mean circumcision and ring removal times were 7.4 ± 3.2 and 4.4 ± 4.2 min, respectively. There were four (5%) moderate AEs, which were managed conservatively. No severe AEs occurred. The mean time to complete clinical healing was 29.8 ± 7.3 days. Participants or their parents liked ShangRing circumcision because it improved hygiene, was quick and possessed an excellent cosmetic appearance. Most (72/80, 94.7%) were very satisfied with the appearance of the circumcised penis, and all (100%) said they would recommend circumcision to others.

Conclusions: Our results suggest that no-flip ShangRing VMMC is safe and acceptable in boys below 18 years of age. Our results are to be compared those seen following ShangRing VMMC in African men. Further study with larger sample sizes are needed to explore the scalability of the ShangRing in larger paediatric cohorts in Africa. We believe that the ShangRing has great potential for use in all age groups from neonates to adults, which would simplify device implementation.

Keywords: Male circumcision; ShangRing; adolescents; circumcision device; infants.

Conflict of interest statement

The authors declare no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

References

    1. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A.. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med. 2005. October 25;2(11):e298.
    1. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007. February 24;369(9562):643–8.
    1. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657–66.
    1. Mehta SD, Moses S, Agot K, Odoyo-June E, Li H, Maclean I, et al. The long-term efficacy of medical male circumcision against HIV acquisition. Aids. 2013. November 28;27(18):2899–2709.
    1. Gray R, Kigozi G, Kong X, Ssempiija V, Makumbi F, Wattya S, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. Aids. 2012. March 13;26(5):609–15.
    1. NASCOP National guidance for VMMC in Kenya – 2008 [Internet]. 2008. [cited 2015 February5]. Available from:
    1. UNAIDS New data on male circumcision and HIV prevention: policy and programme implications [Internet]. [cited 2015. February 5]. Available from:
    1. Sgaier SK, Reed JB, Thomas A, Njeuhmeli E. Achieving the HIV prevention impact of voluntary medical male circumcision: lessons and challenges for managing programs. PLoS Med. 2014. May 6;11(5):e1001641.
    1. UNAIDS, WHO Joint strategic action framework to accelerate the scale-up of voluntary medical male circumcision for HIV prevention in Eastern and Southern Africa. 2011. Available from:
    1. WHO, UNAIDS A framework for voluntary medical male circumcision: VMMC 2021 [Internet]. 2016. [cited 2016 August24]. Available from:
    1. NASCOP (Kenya) National voluntary medical male circumcision strategy, 2014/15-2018/19 [Internet]. 2nd ed 2015. [cited 2016 August24]. Available from:
    1. Morris BJ, Waskett JH, Banerjee J, Wamai RG, Tobian AAR, Gray RH, et al. A ‘snip’ in time: what is the best age to circumcise? BMC Pediatr. 2012. December 28;12(1):20.
    1. Auvert B, Marseille E, Korenromp EL, Lloyd-Smith J, Sitta R, Taljaard D, et al. Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in sub-Saharan Africa. Myer L, editor PLoS One. 2008. August 6;3(8):e2679.
    1. Sokal DC, Li PS, Zulu R, Awori QD, Agot K, Simba RO, et al. Field study of adult male circumcision using the ShangRing in routine clinical settings in Kenya and Zambia. Jaids. 2014. December 1;67(4):430–37.
    1. Kigozi G, Musoke R, Watya S, Kighoma N, Ssebbowa P, Serwadda D, et al. The acceptability and safety of the Shang Ring for adult male circumcision in Rakai, Uganda. Jaids. 2013. August 15;63(5):617–21.
    1. Sokal DC, Li PS, Zulu R, Awori QD, Combes SL, Simba RO, et al. Randomized controlled trial of the ShangRing versus conventional surgical techniques for adult male circumcision. Jaids. 2014. April 1;65(4):447–55.
    1. Mutabazi V, Kaplan SA, Rwamasirabo E, Bitega JP, Ngeruka ML, Savio D, et al. HIV prevention. Jaids. 2012. September 1;61(1):49–55.
    1. WHO prequalification of male circumcision devices PUBLIC report Product: PrePex Number : PQMC 0001-001-00 Abstract Summary of prequalification status for PrePex. 2013.
    1. Barone MA, Awori QD, Li PS, Simba RO, Weaver MA, Okech JO, et al. Randomized trial of the ShangRing for adult male circumcision with removal at one to three weeks. Jaids. 2012. July 1;60(3):e82–9.
    1. Kigozi G, Musoke R, Kighoma NGR. The acceptability and safety of the ShangRing for adolescent male circumcision in Rakai, Uganda. International AIDS Society Conference; 2014; Melbourne, Australia TUPE148 p.
    1. Barone MA, Li PS, Awori QD, Lee R, Goldstein M. Clinical trials using the Shang Ring device for male circumcision in Africa: a review. Transl Androl Urol. 2014;3(1):113–24.
    1. Yan B, You H, Zhang K, Tang H, Mao W, He G, et al. Circumcision with the Chinese ShangRing in children: outcomes of 824 cases. Natl J Andrology- China. 2010. March;16(3):250–53.
    1. Pan F, Pan L, Zhang A, Liu Y, Zhang F, Dai Y. Circumcision with a novel disposable device in Chinese children: a randomized controlled trial. Int J Urol. 2013. February;20(2):220–26.
    1. Cao D-H, Liu L-R, Yang L, Qian S-Q, Lei J-H, Yuan J-H, et al. No-flip method versus external method for ShangRing circumcision: a meta-analysis. Natl J Andrology- China. 2014. December;20(12):1113–19.
    1. ODK Open data kit [Internet]. 2014. [cited 2014 November28]. Available from:
    1. Rech D, Samkange C, Ridzon R, Dickson K. Adverse event action guide for male circumcision. Washington (DC): PSI and WHO; 2011.
    1. Barone MA, Ndede F, Li PS, Masson P, Awori Q, Okech J, et al. The ShangRing device for adult male circumcision: a proof of concept study in Kenya. Jaids. 2011. May 1;57(1):e7–12.
    1. Garra G, Singer AJ, Domingo A, Thode HC. The Wong-Baker pain FACES scale measures pain, not fear. Pediatr Emerg Care. 2013. January;29(1):17–20.
    1. Tyler DC, Tu A, Douthit J, Chapman CR. Toward validation of pain measurement tools for children: a pilot study. Pain. 1993. March;52(3):301–09.
    1. Tshimanga M, Hatzold K, Mugurungi O, Mangwiro T, Ncube G, Xaba S, et al. Safety profile of Prepex male circumcision device and client satisfaction with adolescent males aged 13–17 years in Zimbabwe. Jaids. 2016. June 1;72:S36–42.
    1. Yang B-H, Jia C, Liu T, Peng Y-F. Novel no-flip Shang Ring circumcision for adult males: a clinical application study of 528 cases. Natl J Andrology- China. 2014. August;20(8):709–14.
    1. Yan B, You H, Simplified A. No flip ShangRing technique for adolescents. Natl J ofAndrology. 2010;16(3):250–53.
    1. Bermudez DM, Canning DA, Liechty KW. Age and pro-inflammatory cytokine production: wound-healing implications for scar-formation and the timing of genital surgery in boys. J Pediatr Urol. 2011. June;7(3):324–31.
    1. Zitsman JL. Risks from circumcision during the first month of life compared with those for uncircumcised boys. J Pediatr Surg. 1990. January 1;25(1):174.
    1. Binagwaho A, Pegurri E, Muita J, Bertozzi S. Male circumcision at different ages in Rwanda: a cost-effectiveness study. Kalichman SC, editor PLoS Med. 2010. January 19;7(1):e1000211.
    1. WHO, JHPIEGO Manual for early infant male circumcision under local anaesthesia. 2010.
    1. Young M, Odoyo-June E, Nordstrom SK, Irwin TE, Ongong’a DO, Ochomo B, et al. Factors associated with uptake of infant male circumcision for HIV prevention in Western Kenya. Pediatrics. 2012. July;130(1):e175–82.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa